Real-World study tracks Durvalumab's safety and effectiveness in russian lung cancer patients
NCT ID NCT05456867
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 250 adults in Russia with advanced, inoperable non-small cell lung cancer who are receiving durvalumab after chemoradiation. Researchers will track side effects, treatment duration, and outcomes to see how the drug performs in routine clinical practice. The goal is to gather real-world data to help optimize treatment for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab
What this could lead to
If successful, this study could help doctors understand how to better use durvalumab in everyday practice, potentially improving treatment plans for lung cancer patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by real-world factors. It cannot prove cause and effect, and findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Arkhangelsk, Russia
-
Research Site
Chelyabinsk, Russia
-
Research Site
Grozny, Russia
-
Research Site
Irkutsk, Russia
-
Research Site
Khanty-Mansiysk, Russia
-
Research Site
Kostroma, Russia
-
Research Site
Krasnodar, Russia
-
Research Site
Krasnoyarsk, Russia
-
Research Site
Moscow, Russia
-
Research Site
Murmansk, Russia
-
Research Site
Nizhny Novgorod, Russia
-
Research Site
Novosibirsk, Russia
-
Research Site
Perm, Russia
-
Research Site
Saint Petersburg, Russia
-
Research Site
Sochi, Russia
-
Research Site
Surgut, Russia
-
Research Site
Tomsk, Russia
-
Research Site
Ufa, Russia
-
Research Site
Vologda, Russia
-
Research Site
Yaroslavl, Russia
-
Research Site
Yekaterinburg, Russia
-
Research Site
Yuzhno-Sakhalinsk, Russia